192718-06-2
192718-06-2 性质
| 沸点 | 488.6±47.0 °C(Predicted) |
|---|---|
| 密度 | 1.433±0.06 g/cm3(Predicted) |
| 储存条件 | Sealed in dry,Room Temperature |
| 溶解度 | 在DMSO中的溶解度为0.3mg/mL，澄清（加热） |
| 酸度系数(pKa) | -4.21±0.20(Predicted) |
| 形态 | 粉末 |
| 颜色 | 淡黄色至深黄色 |
192718-06-2 用途与合成方法
0.88 μM (USP1)
Pretreatment of USP1/UAF1 with C527 resulted in inhibition of its enzyme activity with an IC 50 of 0.88±0.03 μM. C527 inhibits the DUB activity of the USP12/USP46 complex and other DUB enzymes in vitro . However, the IC 50 of C527 for these DUB enzymes was higher in comparison with USP1/UAF1 complex. C527 has considerably less inhibitory effect on UCH-L1 and UCH-L3, a different subclass of DUB enzymes. C527 treatments causes an increase in the levels of Ub-FANCD2 and Ub-FANCI. Pretreatment of cells with the C527 causes an enhancement in the cytoxicity of mitomycin C and camptothecin. C527 treatments lead to an increase in ubiquitinated forms of FANCD2 and FANCI, cause a decrease in homologous recombination activity, and sensitize cells to DNA damaging agents.
192718-06-2 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-12988 | 192718-06-2 | 1 mg | 120 | |
| 2026-09-15 | HY-12988 | 192718-06-2 | 192718-06-2 | 5mg | 300 |
